Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid))
Hladun, Raquel (Hospital Universitari Vall d'Hebron)
De Álava, Enrique (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Álvarez, R. (Hospital General Universitario Gregorio Marañón)
Bautista, F. (Hospital Infantil Universitario Niño Jesús (Madrid))
López-Ríos, F. (Hospital Universitario HM Sanchinarro (Madrid))
Colomer, Ramon (Hospital Universitario de la Princesa (Madrid))
Rojo, F. (Sociedad Española de Anatomía Patológica)
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	The recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the development of specific fusion protein inhibitors, such as larotrectinib and entrectinib, have revolutionised the diagnostic and clinical management of patients presenting with tumours with these alterations. Tumours that harbour NTRK fusions are found in both adults and children; and they are either rare tumours with common NTRK fusions that may be diagnostic, or more prevalent tumours with rare NTRK fusions. To assess currently available evidence on this matter, three key Spanish medical societies (the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Pathological Anatomy (SEAP), and the Spanish Society of Paediatric Haematology and Oncology (SEHOP) have brought together a group of experts to develop a consensus document that includes guidelines on the diagnostic, clinical, and therapeutic aspects of NTRK -fusion tumours. This document also discusses the challenges related to the routine detection of these genetic alterations in a mostly public Health Care System.
Grants:	Instituto de Salud Carlos III PI11/02866 Instituto de Salud Carlos III PI14/01176 Instituto de Salud Carlos III PI7/01001 Instituto de Salud Carlos III PI17/00464
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Gene fusions ; Molecular oncology ; Mutations ; Neoplasm ; Target therapies
Published in:	Clinical & translational oncology, Vol. 23 (february 2021) , p. 1529-1541, ISSN 1699-3055

DOI: 10.1007/s12094-021-02558-0
PMID: 33620682

13 p, 1.1 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles